CVS Health Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVS research report →
Range $103 – $123
Price Chart
About the company
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other.
- CEO
- J. David Joyner
- IPO
- 1973
- Employees
- 259,500
- HQ
- Woonsocket, RI, US
AI snapshot
Six angles, distilled from the data.
CVS is in a broad sideways-to-recovery regime after a long reset, trading near its 200-day average and well below the 52-week high. That leaves the setup constructive but not broken out; shareholders should watch whether it can hold the upper end of the multi-month range and build on the recent stabilization.
Street sentiment is constructive, with a Buy consensus and an average target around 110.56 versus a last close of 89.79. Recent calls have mostly been reiterated rather than upgraded, while several targets were trimmed into the low-100s, signaling confidence in the story but less enthusiasm than earlier in the year.
CVS has a clean beat streak, going 8-for-8 on EPS with the latest quarter topping by 29.0%. Next-year EPS estimates sit at 8.6782, slightly above the 8.61 TTM level, so the key watchpoint is whether management can keep earnings momentum intact while revenue growth and margin recovery stay on track.
The signal is mixed but leans negative: one discretionary buy from an EVP was outweighed by heavy director selling, including a very large block from Larry Robbins. Most other filings were award, in-kind, or return-related activity, which is less informative than the outright sales.
Profitability is solid but not elite, with a 3.06% operating margin, 2.64% net margin, and 14.36% ROE. Growth is improving, with revenue up 5.4% year over year and EPS growth of 188.8%, while free cash flow of $13.471 billion and an 11.78% FCF yield support the equity story.
CVS screens as a value-oriented healthcare services name, with a 11.4 P/E that is modest for the sector. The market is paying for scale, cash generation, and earnings consistency, but the balance sheet remains leveraged with $79.95 billion of total debt and $69.352 billion of net debt.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $103.43B
- P/E
- 9.33
- Fwd P/E
- 9.76
- PEG
- 0.00
- P/S
- 0.25
- P/B
- 1.29
- EV/EBITDA
- 8.48
- Div Yield
- 3.29%
- Gross Margin
- 14.23%
- Op Margin
- 3.58%
- Net Margin
- 2.63%
- ROE
- 14.13%
- ROIC
- 8.05%
Latest fiscal year · YoY change
- Revenue
- $402.07B+7.8%
- Gross Profit
- $55.36B+7.7%
- Op Income
- $4.66B
- Net Income
- $1.77B-61.7%
- EPS
- $1.40-61.7%
- OCF Growth
- +16.8%
- FCF Growth
- +23.4%
- 52W High
- $110.68
- 52W Low
- $69.51
- 50D MA
- $88.71
- 200D MA
- $89.34
- Beta
- 0.58
- RSI (14)
- 37
- Avg Volume
- 9.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CVS Health beat expectations, raised 2026 guidance, and announced plans to separate into two public companies while describing 2027 as a trough year for Health Services before growth resumes.· November 4, 2026
- Q3 adjusted EPS was $2.09, up more than 30% year over year, on over $108 billion of revenue and nearly $4.2 billion of adjusted operating income.
- The company raised full-year 2026 adjusted EPS guidance to at least $8.20 from $7.90-$8.10 and lifted cash flow from operations outlook to at least $15.5 billion.
- Management announced an intention to separate into two listed companies: CVS Health and CVS Pharmacy, with completion targeted for the first half of 2028.
- Healthcare Benefits showed major margin improvement, with adjusted operating income of $900 million and a medical benefit ratio of 91.3%.
- Management said 2027 should be trough earnings for Health Services, while 2027 adjusted EPS is expected to be at least $8.65.
CVS Health reported third-quarter adjusted operating income of nearly $4.2 billion and adjusted EPS of $2.09, with adjusted EPS up over 30% versus the prior year quarter. Revenue was over $108 billion, and cash flow from operations was approximately $4.7 billion, bringing year-to-date cash flow from operations to $15.3 billion. By segment, Healthcare Benefits adjusted operating income was $900 million with a 91.3% medical benefit ratio; Health Services adjusted operating income was $2.1 billion; and Pharmacy and Consumer Wellness adjusted operating income was over $1.6 billion. Full-year 2026 guidance was raised to at least $8.20 in adjusted EPS, at least $420 billion of revenue, at least $5.4 billion of Healthcare Benefits adjusted operating income, at least $6.5 billion of Pharmacy and Consumer Wellness adjusted operating income, at least $17.05 billion of enterprise adjusted operating income, and at least $15.5 billion of cash flow from operations. For 2027, management said adjusted EPS is expected to be at least $8.65, with Health Services adjusted operating income of at least $7 billion and low-single-digit growth in Pharmacy and Consumer Wellness operating income off 2026 guidance.
David Joyner framed the separation as a strategic move from a position of strength, not distress, saying the company has rebuilt its leadership, improved performance, strengthened the balance sheet, and reached target leverage ahead of schedule. He emphasized that the split is meant to create two focused businesses with clearer capital allocation, faster decision-making, and more tailored strategies: a health solutions company and a national retail pharmacy/community health company. His tone was confident and forward-looking, repeatedly stressing momentum, long-term value creation, and the view that technology and AI will shape the next phase of healthcare.
Brian Newman focused on the quarter’s execution, highlighting revenue of over $108 billion, adjusted EPS of $2.09, nearly $4.2 billion of adjusted operating income, and $4.7 billion of quarterly operating cash flow. He said year-to-date operating cash flow reached $15.3 billion, the company ended the quarter with $6 billion of cash at the parent and unrestricted subsidiaries, and leverage goals were achieved ahead of schedule. He also noted the company expects to resume share repurchases in the fourth quarter, and said both future companies should remain solid investment-grade with strong free cash flow. On guidance, he detailed the raises across revenue, EPS, segment operating income, and cash flow, while noting 2027 guidance of $8.65 EPS effectively assumes only dilution from share repurchase timing and that one-time and stranded costs from separation should be manageable.
Analysts focused on the timing and rationale for the split, especially why now, and management said the business is making the decision from strength after two years of operational improvement and eight straight quarters of beat-and-raise performance. Questions also centered on 340B, with management saying the 2027 outlook incorporates a year-over-year decline in 340B and that the issue should not be a major discussion point going forward, while also framing 2027 Health Services earnings as trough levels. Other questions addressed balance sheet implications, capital deployment, and potential dis-synergies; management said both companies should remain investment grade, capital deployment should remain viable, and any transaction costs should be manageable. Analysts also asked about preserving the value created by CVS Pharmacy/Caremark integration, and management answered that the key synergies will be preserved through commercial agreements and a continued focus on Health 100 and consumer engagement.
The call showed broad operational momentum: earnings, revenue, cash flow, and segment profitability all improved, and management raised guidance across the enterprise. Management was confident that 2027 would mark trough earnings for Health Services, with specialty, healthcare delivery, and Pharmacy and Consumer Wellness expected to support growth after that. The planned separation was presented as a way to sharpen focus and unlock value while maintaining key integrations through commercial agreements.
Management flagged 2027 as a year of headwinds for Health Services, including a decline in 340B, lower Caremark membership, and a less robust selling season. They also acknowledged elevated medical cost trends and said the Healthcare Benefits recovery is still a multiyear journey, even if ahead of schedule. The separation itself will bring one-time and stranded public-company costs, and the companies will need to execute over the next 15 to 18 months to preserve the economics of the current integrated model.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.28B
- Float Shares
- 1.28B
of shares held by institutions
2,182 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CVS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Aug 26, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Dwight EvansHouse · PA03 | Sell | Nov 21, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| John BoozmanSenate · AR | Buy | Jan 29, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Dec 11, 24 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 25, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 120.71M | ▲ 1.82M |
| Blackrock, Inc. | 120.39M | ▼ 2.83M |
| Vanguard Capital Management LLC | 83.69M | ▲ 371.00K |
| Capital World Investors | 74.04M | ▼ 908.66K |
| State Street Corp | 60.09M | ▼ 196.14K |
| Dodge & Cox | 46.04M | ▼ 3.97M |
| Wellington Management Group Llp | 33.80M | ▲ 11.23M |
| Geode Capital Management, LLC | 30.92M | ▲ 1.02M |
| Vanguard Portfolio Management LLC | 27.11M | ▲ 473.05K |
| Fmr LLC | 24.88M | ▼ 4.04M |
| Price T Rowe Associates Inc | 24.20M | ▲ 420.74K |
| Bank Of America Corp | 23.19M | ▲ 13.84M |
Held by 2,211 ETFs
Biggest fund positions in CVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Heitsenrether Teresa A | other | 0 |
| Nov 6, 26 | Shah Prem S | buy | 23,855 |
| Jun 26, 26 | Clark James David | other | 454 |
| May 31, 26 | Newman Brian | other | 2,478 |
| May 31, 26 | Compton-Phillips Amy | other | 7,618 |
| May 20, 26 | AGUIRRE FERNANDO | sell | 30,437 |
| May 21, 26 | AGUIRRE FERNANDO | sell | 1,563 |
| May 19, 26 | ROBBINS LARRY | sell | 1,983,387 |
| May 19, 26 | ROBBINS LARRY | sell | 151 |
| May 20, 26 | ROBBINS LARRY | sell | 797,628 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CVS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CVS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
247wallst.com · Nov 20
CVS Pharmacy® names Grand Prize winners of first Home Team Heroes youth soccer contest
prnewswire.com · Nov 20
Aetna Commits to Connecting 90% of Members to Essential, End-to-End Maternal and Infant Care by 2032 with Launch of the Aetna For You & Baby Initiative
prnewswire.com · Nov 19
CVS Health Raised Its 2026 Outlook 3 Times, but Not Its Dividend
247wallst.com · Nov 18
4 High-Yield Healthcare Stocks Retirees Should Buy for December Income
247wallst.com · Nov 18
Why CVS Health (CVS) is a Top Growth Stock for the Long-Term
zacks.com · Nov 17
CVS Health Earns Global Recognition for Industry-Leading AI and Technology Innovation
accessnewswire.com · Nov 17
CVS says GLP-1s save money when priced below $350 per month
nypost.com · Nov 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice
